Get the Stockscreener App
0.6675
2.80%
-0.0192
After Hours:
.64
-0.0275
-4.12%
Unicycive Therapeutics Inc stock is traded at $0.6675, with a volume of 7.55M.
It is down -2.80% in the last 24 hours and up +12.02% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$0.6867
Open:
$0.6793
24h Volume:
7.55M
Relative Volume:
2.65
Market Cap:
$64.19M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.4306
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
+5.97%
1M Performance:
+12.02%
6M Performance:
+1.44%
1Y Performance:
+3.36%
1-Day Range:
$0.601
$0.6899
1-Week Range:
$0.6008
$0.7576
52-Week Range:
$0.202
$1.10
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.6675 | 64.19M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing By Investing.com - Investing.com South Africa
Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split - MarketScreener
Unicycive Therapeutics (UNCY) Announces 1-for-10 Reverse Stock S - GuruFocus
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing - Investing.com
Unicycive Therapeutics Announces Reverse Stock Split - marketscreener.com
Unicycive Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
Kaplan Fox Alerts Investors of Unicycive Therapeutics to an Investigation of Possible Securities Law Violations - FinancialContent
Equities Analysts Offer Predictions for UNCY Q3 Earnings - Defense World
Kaplan Fox is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - The Globe and Mail
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m - Yahoo Finance
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy By Investing.com - Investing.com South Africa
Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
Unicycive Therapeutics Stock: FDA Halts Progress on Key Drug - sharewise
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues - Investing.com Australia
Unicycive Therapeutics Stock Is Trading Lower Tuesday: What's Going On? - Benzinga
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues By Investing.com - Investing.com Nigeria
Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues - Endpoints News
UNCY Stock Drops Amid FDA Manufacturing Deficiencies - GuruFocus
Unicycive drops after FDA finds drug manufacturing issues - Seeking Alpha
Unicycive Says US FDA Inspection Reveals Manufacturing Deficiencies for Oxylanthanum Carbonate Drug Candidate; Shares Down - MarketScreener
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy - Investing.com Australia
Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia - marketscreener.com
Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025 - Nasdaq
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Provides Update on New Drug Application for - GlobeNewswire
FDA Manufacturing Concerns Delay Unicycive's Crucial Kidney Disease Drug Approval Process - Stock Titan
Unicycive Therapeutics reports annual meeting outcomes By Investing.com - Investing.com Canada
Unicycive Therapeutics reports annual meeting outcomes - Investing.com
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stake Boosted by Northern Trust Corp - Defense World
Unicycive Therapeutics (UNCY) Receives Buy Rating with Promising Future | UNCY Stock News - GuruFocus
PROREIT ANNOUNCES VOTING RESULTS AND EXPIRY OF RIGHTS PLAN - The Globe and Mail
JPMorgan Chase Is One of the Largest Financial Companies by Market Cap. But Is It a Buy? - The Globe and Mail
Unicycive Therapeutics (UNCY) Stock Price, News & Analysis - MarketBeat
Q2 Earnings Estimate for UNCY Issued By HC Wainwright - Defense World
Biotech Stocks Facing FDA Decision In June 2025 - RTTNews
Brokers Offer Predictions for UNCY Q4 Earnings - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Unicycive Therapeutics (UNCY): HC Wainwright & Co. Sets Price Ta - GuruFocus
Unicycive Therapeutics (UNCY): HC Wainwright & Co. Sets Price Target | UNCY Stock News - GuruFocus
Unicycive Therapeutics (UNCY) Receives Buy Rating with Promising FDA Outlook | UNCY Stock News - GuruFocus
Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences - Nasdaq
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Benchmark maintains $3 target on Unicycive stock post-Q1 filings By Investing.com - Investing.com Canada
Unicycive Therapeutics Updates Annual Meeting Time - TipRanks
Unicycive Therapeutics (UNCY) Alters 2025 Shareholder Meeting Time | UNCY Stock News - GuruFocus
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewswire
Unicycive Therapeutics Updates Annual Meeting Schedule: Key Details for Kidney Disease Biotech Investors - Stock Titan
These Numbers Show Just How Powerful Unicycive Therapeutics Inc (NASDAQ: UNCY) Stock Is - Stocksregister
Q2 Earnings Forecast for UNCY Issued By Noble Financial - Defense World
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):